Canada markets close in 20 minutes

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
7.75+0.01 (+0.13%)
As of 01:45PM EDT. Market open.
Full screen
Previous Close7.74
Open8.00
Bid7.75 x 0
Ask7.99 x 0
Day's Range7.75 - 8.00
52 Week Range6.76 - 10.00
Volume1,351
Avg. Volume5,467
Market Cap94.446M
Beta (5Y Monthly)0.89
PE Ratio (TTM)15.50
EPS (TTM)0.50
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    BioSyent to Present at the Virtual MicroCap Leadership Summit

    MISSISSAUGA, Ontario, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been selected to present at the 7th annual MicroCap Leadership Summit on Friday, September 16th, 2022. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activities. The MicroCap Leadership Summit is attended by retail and institutional investors from around the world. BioSye

  • GlobeNewswire

    BioSyent Announces Adoption of Dividend Policy

    MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors (the “Board”) today adopted a Dividend Policy in order to establish terms of reference for the Board in its decision-making around the declaration of any dividends to be issued to shareholders of the Company. “The adoption of a Dividend Policy by the Board is an important step in our evolution as a Company and a formal recognition o

  • GlobeNewswire

    BioSyent Releases Q2 and H1 2022 Financial Results

    MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2022. Key highlights include: Second quarter (Q2) 2022 Total Company Net Revenues of $6,634,875 decreased by 9% versus Q2 2021First half (H1) 2022 Total Company Net Revenues of $13,672,286 decreased by 7% versus H1 2021Q2 2022 Canadian Pharmaceutical Net Revenues from continuing brands of $6,272,185 increased by 1% ve